 Disease-Free Survival
"Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
| Descriptor ID |
D018572
|
| MeSH Number(s) |
E01.789.200 E05.318.740.998.300 N05.715.360.750.795.300 N06.850.520.830.998.300
|
| Concept/Terms |
Disease-Free Survival- Disease-Free Survival
- Disease Free Survival
- Event-Free Survival
- Event Free Survival
- Event-Free Survivals
- Survival, Event-Free
- Survivals, Event-Free
- Survival, Disease-Free
- Disease-Free Survivals
- Survival, Disease Free
- Survivals, Disease-Free
Progression-Free Survival- Progression-Free Survival
- Progression Free Survival
- Progression-Free Survivals
- Survival, Progression-Free
- Survivals, Progression-Free
|
Below are MeSH descriptors whose meaning is more general than "Disease-Free Survival".
Below are MeSH descriptors whose meaning is more specific than "Disease-Free Survival".
This graph shows the total number of publications written about "Disease-Free Survival" by people in this website by year, and whether "Disease-Free Survival" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 6 | 6 | | 1996 | 0 | 4 | 4 | | 1997 | 0 | 7 | 7 | | 1998 | 0 | 8 | 8 | | 1999 | 0 | 3 | 3 | | 2000 | 0 | 9 | 9 | | 2001 | 0 | 11 | 11 | | 2002 | 0 | 9 | 9 | | 2003 | 0 | 9 | 9 | | 2004 | 0 | 14 | 14 | | 2005 | 0 | 8 | 8 | | 2006 | 0 | 10 | 10 | | 2007 | 0 | 13 | 13 | | 2008 | 0 | 15 | 15 | | 2009 | 0 | 14 | 14 | | 2010 | 0 | 24 | 24 | | 2011 | 0 | 19 | 19 | | 2012 | 0 | 33 | 33 | | 2013 | 0 | 39 | 39 | | 2014 | 0 | 39 | 39 | | 2015 | 0 | 41 | 41 | | 2016 | 0 | 42 | 42 | | 2017 | 0 | 53 | 53 | | 2018 | 0 | 12 | 12 | | 2019 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Disease-Free Survival" by people in Profiles.
-
Mehra MR, Uriel N, Naka Y, Cleveland JC, Yuzefpolskaya M, Salerno CT, Walsh MN, Milano CA, Patel CB, Hutchins SW, Ransom J, Ewald GA, Itoh A, Raval NY, Silvestry SC, Cogswell R, John R, Bhimaraj A, Bruckner BA, Lowes BD, Um JY, Jeevanandam V, Sayer G, Mangi AA, Molina EJ, Sheikh F, Aaronson K, Pagani FD, Cotts WG, Tatooles AJ, Babu A, Chomsky D, Katz JN, Tessmann PB, Dean D, Krishnamoorthy A, Chuang J, Topuria I, Sood P, Goldstein DJ. A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. N Engl J Med. 2019 04 25; 380(17):1618-1627.
-
Moreira DC, Macy ME, Cost CR, Greffe BS, Garrington TP. Central Nervous System Involvement of Rhabdomyosarcoma: A Single Institution Experience. J Pediatr Hematol Oncol. 2019 03; 41(2):152-154.
-
Arrieta-Bolaños E, Crivello P, Shaw BE, Ahn KW, Wang HL, Verneris MR, Hsu KC, Pidala J, Lee SJ, Fleischhauer K, Spellman SR. In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance. Blood Adv. 2018 07 24; 2(14):1773-1783.
-
Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS, Ready NE, Zhang W, Wallin J, Funke R, Waterkamp D, Foster P, Iizuka K, Powderly J. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer. 2018 09; 101:114-122.
-
Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil L. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018 06 12; 2(11):1334-1343.
-
Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 07 26; 379(4):341-351.
-
Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R. Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease? Am J Clin Pathol. 2018 May 31; 150(1):34-42.
-
Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, Vo A, Hamilton E. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 07; 19(7):880-888.
-
Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Oki Y, Fayad LE, Medeiros LJ, Dabaja BS, Nastoupil LJ. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. Leuk Lymphoma. 2018 12; 59(12):2896-2903.
-
Tsai TC, Miller J, Andolfi C, Whang B, Fisichella PM. Surgical evaluation of lymph nodes in esophageal adenocarcinoma: Standardized approach or personalized medicine? Eur J Surg Oncol. 2018 08; 44(8):1177-1180.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|